SCHEMBL29344162

SCHEMBL29344162

Cc1cc(Cl)c(OC(F)(F)F)c(Br)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.42
MEN1 O00255 5/20 0.42
KDM4E B2RXH2 5/20 0.41
ALDH1A1 P00352 3/20 0.40
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 2/20 0.37
LMNA P02545 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPY1R P25929 1/20 0.36
NPY2R P49146 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 2/20 0.35
HTT P42858 1/20 0.35
POLB P06746 1/20 0.33
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.31
MAPK1 P28482 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL671153 0.86 MAPT (0.35) KMT2AMEN1KDM4EALDH1A1CYP3A4
SCHEMBL22954647 0.81 CA1 (0.34) ALDH1A1CYP3A4
SCHEMBL26231908 0.78 WDR5 (0.35)
SCHEMBL29344158 0.78 HSD17B10 (0.37) CYP3A4HPGD
SCHEMBL20763063 0.76 PGK1 (0.40)
SCHEMBL27302981 0.73 CYP1A2 (0.30) CYP1A2
SCHEMBL29937196 0.73 MEN1 (0.34) KMT2AMEN1KDM4EALDH1A1CYP1A2
SCHEMBL29344235 0.71 RAPGEF4 (0.33) KMT2AMEN1KDM4EALDH1A1HTT
SCHEMBL29344159 0.71 LPL (0.33)
SCHEMBL13855834 0.70 AKR1C2 (0.32) KMT2AMEN1CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT KRAS, NRAS, HRAS KMT2A 1154/4885MEN1 538/4885KDM4E 3110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.